H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Proceedings ArticleDOI
Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer
Jeffrey R. Infante,E. Claire Dees,Howard A. Burris,Leigh Zawel,Jason A. Sager,Claudina Stevenson,Kathryn Clarke,S. Dhuria,Dale Porter,Suman Sen,Erika Aina Zannou,Sushil K. Sharma,Roger B. Cohen +12 more
TL;DR: Oral LCL161 is well tolerated, has dose-proportional PK, and demonstrates target inhibition in patients, as demonstrated by cIAP degradation and cytokine induction in patients.
Journal ArticleDOI
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Denise A. Yardley,Linda D. Bosserman,Joyce O'Shaughnessy,William N. Harwin,Susan Kay Morgan,Victor M. Priego,N. W. Peacock,J. David Bass,Howard A. Burris,John D. Hainsworth +9 more
TL;DR: The addition of everolimus did not improve the efficacy of weekly paclitaxel/bevacizumab as first-line treatment for patients with HER2-negative MBC, and these results contrast with the demonstrated efficacy of addingEverolimus to either hormonal or Her2-targeted therapy in previously treated patients.
Journal ArticleDOI
Long-term follow-up of the PI3K{delta} inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.
Howard A. Burris,Ian W. Flinn,Matthew A. Lunning,Julie M. Vose,Nathan Fowler,Loretta J. Nastoupil,Susan O'Brien,Marshall T. Schreeder,Manish R. Patel,Timothy S. Fenske,Danielle M. Brander,Tanya Siddiqi,Christopher R. Flowers,Jan A. Burger,William G. Wierda,John G. Kuhn,Peter Sportelli,Hari P. Miskin,Michael S. Weiss,Owen A. O'Connor +19 more
TL;DR: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differentiated safety profile from other PI3kδ inhibitors, and demonstrated activity in patients with advanced hematologic needs.
Journal ArticleDOI
Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy
Mario Campone,J. Thaddeus Beck,Michael Gnant,Patrick Neven,Kathleen I. Pritchard,Thomas Bachelot,Louise Provencher,Hope S. Rugo,Martine Piccart,Gabriel N. Hortobagyi,Martina Nunzi,Daniel Y.C. Heng,José Baselga,Anna Komorowski,Shinzaburo Noguchi,Jun Horiguchi,Lee Bennett,Ryan Ziemiecki,Jie Zhang,Ayelet Cahana,Tetiana Taran,Tarek Sahmoud,Howard A. Burris +22 more
TL;DR: These analyses confirm that EVE’s+ EXE provides clinical benefit without adversely impacting HRQOL in patients with HR+ ABC who recurred/progressed on prior NSAIs versus endocrine therapy alone.
Journal ArticleDOI
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Colin D. Weekes,Albert C. Lockhart,Patricia LoRusso,Elaine Murray,Erica Park,Mike Tagen,Jatinder Singh,Indrani Sarkar,Lars Mueller,Hatem Dokainish,Geoffrey I. Shapiro,Howard A. Burris +11 more
TL;DR: The safety profile of MEK and ERK inhibition demonstrated classic MAPK inhibitor-related adverse events (AEs), however, overlapping AEs and cumulative toxicity could not be adequately managed on either dosing schedule, restricting the ability to further develop this combination.